Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.89 |
| ▸ | MEN1 | O00255 | 4/20 | 0.89 |
| ▸ | TP53 | P04637 | 4/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.89 |
| ▸ | GMNN | O75496 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 1/20 | 0.89 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | THPO | P40225 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL26077 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL6365 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL4019370 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL178086 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL17164701 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL5328781 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL10336277 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL7744729 | 0.92 | ESR1 (0.96) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL5322913 | 0.91 | ESR1 (0.94) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL2406557 | 0.90 | ESR1 (0.84) | ESR1ESR2MEN1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242098-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH LLC (US) | 2012-08-14 | — | — | US | claimed |
| US-7488734-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2009-02-10 | — | — | US | claimed |
| US-7192956-B2 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH (US) | 2007-03-20 | — | — | US | claimed |
| EP-1531806-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1531806-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | claimed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | claimed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| WO-2004000225-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-8242098-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7488734-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000225-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | GPER1, OXTR, SHBG | ESR1 22/4885ESR2 7/4885MEN1 482/4885 |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | OXTR, GNRHR, SHBG | ESR1 9/4885ESR2 6/4885MEN1 485/4885 |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | ESR1 49/4885ESR2 9/4885MEN1 402/4885 |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | OXTR, GNRHR, SHBG | ESR1 9/4885ESR2 6/4885MEN1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.